244 related articles for article (PubMed ID: 8390533)
21. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
22. gp140, the EBV/C3d receptor (CR2) of human B lymphocytes, is involved in cell-free phosphorylation of p120, a nuclear ribonucleoprotein.
Delcayre AX; Fiandino A; Barel M; Frade R
Eur J Immunol; 1987 Dec; 17(12):1827-33. PubMed ID: 2446881
[TBL] [Abstract][Full Text] [Related]
23. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tumor necrosis factor-alpha transcription by Epstein-Barr virus.
Gosselin J; Menezes J; D'Addario M; Hiscott J; Flamand L; Lamoureux G; Oth D
Eur J Immunol; 1991 Jan; 21(1):203-8. PubMed ID: 1846816
[TBL] [Abstract][Full Text] [Related]
26. Activation of human thymocytes after infection by EBV.
Paterson RL; Kelleher CA; Streib JE; Amankonah TD; Xu JW; Jones JF; Gelfand EW
J Immunol; 1995 Feb; 154(3):1440-9. PubMed ID: 7822809
[TBL] [Abstract][Full Text] [Related]
27. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
28. Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.
Chodosh J; Gan Yj; Holder VP; Sixbey JW
Virology; 2000 Jan; 266(2):387-96. PubMed ID: 10639323
[TBL] [Abstract][Full Text] [Related]
29. Structure of the Epstein-Barr virus major envelope glycoprotein.
Szakonyi G; Klein MG; Hannan JP; Young KA; Ma RZ; Asokan R; Holers VM; Chen XS
Nat Struct Mol Biol; 2006 Nov; 13(11):996-1001. PubMed ID: 17072314
[TBL] [Abstract][Full Text] [Related]
30. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
31. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
Servis C; Lambris JD
J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
[TBL] [Abstract][Full Text] [Related]
32. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R
Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992
[TBL] [Abstract][Full Text] [Related]
33. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
34. Murine complement receptor gene family. II. Identification and characterization of the murine homolog (Cr2) to human CR2 and its molecular linkage to Crry.
Kurtz CB; Paul MS; Aegerter M; Weis JJ; Weis JH
J Immunol; 1989 Sep; 143(6):2058-67. PubMed ID: 2528587
[TBL] [Abstract][Full Text] [Related]
35. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression.
Masilamani M; von Seydlitz E; Bastmeyer M; Illges H
Immunobiology; 2002 Dec; 206(5):528-36. PubMed ID: 12607728
[TBL] [Abstract][Full Text] [Related]
36. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.
Fischer E; Delibrias C; Kazatchkine MD
J Immunol; 1991 Feb; 146(3):865-9. PubMed ID: 1703182
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins.
Rayhel EJ; Dehoff MH; Holers VM
J Immunol; 1991 Mar; 146(6):2021-6. PubMed ID: 1706386
[TBL] [Abstract][Full Text] [Related]
38. Expression of EBV/C3d receptors on T cells: biological significance.
Tsoukas CD; Lambris JD
Immunol Today; 1993 Feb; 14(2):56-9. PubMed ID: 8383497
[TBL] [Abstract][Full Text] [Related]
39. The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells.
Lin CT; Lin CR; Tan GK; Chen W; Dee AN; Chan WY
Am J Pathol; 1997 May; 150(5):1745-56. PubMed ID: 9137098
[TBL] [Abstract][Full Text] [Related]
40. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes.
Barel M; Gauffre A; Lyamani F; Fiandino A; Hermann J; Frade R
J Immunol; 1991 Aug; 147(4):1286-91. PubMed ID: 1831222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
